Verrica Pharmaceuticals (VRCA) FCF Margin (2021 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly FCF Margin of 183.16% for Q1 2026, up 18547.0% year-over-year from N/an in Q1 2025, and down 102.75% quarter-over-quarter from 90.34% in Q4 2025.
Verrica Pharmaceuticals (VRCA) FCF Margin (2021 - 2026) Analysis & Trends
Verrica Pharmaceuticals' FCF Margin history runs 6 years deep, the most recent figure standing at 183.16% for Q1 2026.
- In Q1 2026, FCF Margin rose 18547.0% year-over-year to 183.16%; the TTM figure through Mar 2026 stood at 38.0% (up 46180.0% YoY), while the FY2025 annual figure was 49.47%, up 75616.0% from the prior year.
- FCF Margin for Q1 2026 stood at 183.16%, down from 90.34% in the prior quarter.
- The five-year high for FCF Margin was 67.77% in Q3 2025, with the low at 12435.14% in Q1 2023.
- The 5-year median for FCF Margin is 509.98% (2023), against an average of 2097.14%.
- The sharpest annual moves came in 2023 and 2024: FCF Margin tumbled 1049894 bps in 2023, then surged 1191378 bps in 2024.
- Verrica Pharmaceuticals' FCF Margin stood at 7382.35% in 2022, then soared by 90 bps to 741.15% in 2023, then plunged by 530 bps to 4669.77% in 2024, then soared by 98 bps to 90.34% in 2025, then tumbled by 103 bps to 183.16% in 2026.
- Business Quant data shows VRCA's FCF Margin at 183.16% in Q1 2026, 90.34% in Q4 2025, and 67.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 70.82% |
| 10 | Verrica Pharmaceuticals | 101.84 Mn | 90.64 Mn | - | -157.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -157.64% |
| Mar 31, 2026 | -183.16% |
| Dec 31, 2025 | -90.34% |
| Sep 30, 2025 | 67.77% |
| Jun 30, 2025 | -79.07% |
| Mar 31, 2025 | -368.62% |
| Dec 31, 2024 | -4,669.77% |
| Sep 30, 2024 | -481.41% |
| Jun 30, 2024 | -316.19% |
| Mar 31, 2024 | -521.35% |
| Dec 31, 2023 | -741.15% |
| Sep 30, 2023 | -509.98% |
| Jun 30, 2023 | -2,597.80% |
| Mar 31, 2023 | -12,435.14% |
| Dec 31, 2022 | -7,382.35% |
| Sep 30, 2022 | 21.01% |
| Jun 30, 2022 | -3,427.57% |
| Mar 31, 2022 | -1,936.19% |
| Mar 31, 2021 | -92.47% |